- $32.61m
- $31.37m
- $0.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.6 | ||
| Price to Tang. Book | 4.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 26.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -153.28% | ||
| Return on Equity | -103.36% | ||
| Operating Margin | -1175.16% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.12 | 4.07 | 0.9 | 0.4 | 0.91 | 1.24 | 1.4 | -16.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Directors
- Richard Prins NEC (64)
- Ram Mukunda PRE (62)
- Claudia Grimaldi CFO (50)
- Rohit Goel CAO (27)
- John Lynch IND (83)
- Jim Moran IND
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 29th, 2005
- Public Since
- April 13th, 2006
- No. of Shareholders
- 37
- No. of Employees
- 61
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 66,541,532
- Address
- 2405 York Road, Suite 201, LUTHERVILLE-TIMONIUM, 21093-2264
- Web
- https://igcpharma.com/
- Phone
- +1 3019830998
- Auditors
- Manohar Chowdhry & Associates
Upcoming Events for IGC
Q1 2025 IGC Pharma Inc Earnings Release
IGC Pharma Inc Annual Shareholders Meeting
Similar to IGC
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
What is the IGC Pharma share price?
As of Today at 19:11 UTC, shares in IGC Pharma are trading at $0.49. This share price information is delayed by 15 minutes.
How has the IGC Pharma share price performed this year?
Shares in IGC Pharma last closed at $0.49 and the price had moved by +32.25% over the past 365 days. In terms of relative price strength the IGC Pharma share price has outperformed the S&P500 Index by +10.06% over the past year.
What are the analyst and broker recommendations for IGC Pharma?
The overall consensus recommendation for IGC Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the IGC Pharma dividend yield?
IGC Pharma does not currently pay a dividend.
Does IGC Pharma pay a dividend?
IGC Pharma does not currently pay a dividend.
When does IGC Pharma next pay dividends?
IGC Pharma does not currently pay a dividend.
How do I buy IGC Pharma shares?
To buy shares in IGC Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IGC Pharma?
As of the previous close price of $0.49, shares in IGC Pharma had a market capitalisation of $32.61m.
Where are IGC Pharma shares listed?
Here are the trading details for IGC Pharma:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: IGC
What kind of share is IGC Pharma?
Based on an overall assessment of its quality, value and momentum IGC Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IGC Pharma share price forecast for 2024?
The analyst consensus target price for shares in IGC Pharma is $3.25. That is 563.27% above the last closing price of $0.49.
Analysts covering IGC Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.22 for the next financial year.
What is the trend in the IGC Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IGC Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +34.98%.
As of the last closing price of $0.49, shares in IGC Pharma were trading +43.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IGC Pharma PE Ratio?
The IGC Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IGC Pharma?
IGC Pharma's management team is headed by:
- Richard Prins - NEC
- Ram Mukunda - PRE
- Claudia Grimaldi - CFO
- Rohit Goel - CAO
- John Lynch - IND
- Jim Moran - IND